Exploration of Pomalidomide for Heterobifunctional Protein Degraders: From Chemistry to Application

Simple item page
dc.contributor.advisorDerksen, Darren J.
dc.contributor.authorBrownsey, Duncan Keith
dc.contributor.committeememberVan Humbeck, Jeffrey F.
dc.contributor.committeememberBack, Thomas G.
dc.contributor.committeememberLing, Chang-Chun
dc.contributor.committeememberWilliams, Florence J.
dc.date2023-06
dc.date.accessioned2023-04-26T19:51:32Z
dc.date.available2023-04-26T19:51:32Z
dc.date.issued2023-04-04
dc.description.abstractTargeted protein degradation (TPD) has recently come to the forefront of chemical biology and medicinal chemistry as a means to disrupt protein function by selective degradation. Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules that exemplify TPD technology. One of the most widely used E3 ligase ligands in PROTAC development is pomalidomide which make up 46% of all CRBN-targeting PROTACs. This work explores the chemistry of pomalidomide: first by improving the synthesis of pomalidomide derivatives, second by application in new protein degraders of p300, and then third by characterizing the fluorescent properties of pomalidomide. The improved synthesis of pomalidomide derivatives via an SNAr pathway was began by identification and avoidance of the formation of dimethyl pomalidomide, an undesired byproduct. This led to greatly enhanced yields of compounds that can be used to build new pomalidomide containing PROTACs. As well, differences in the reactivity of amines used to create pomalidomide derivatives were exploited to produce PROTACs in one-pot reactions, which in some instances, exceeded the yields of multistep syntheses used in the literature. Secondly, new degraders of the protein target p300 were prepared using a known p300 ligand A-485, outlining a new strategy to create PROTACs. To verify that linker attachment onto A-485 was amenable to PROTAC function, biotin conjugates were installed and verified using immunoprecipitation blots. A library of A-485-pomalidomide conjugates were then prepared and tested for their p300 degradation capability, which showed a general trend that the PROTACs with longer linkers were more effective degraders. Finally, the fluorescent properties of pomalidomide derivatives were explored. In aqueous solutions, pomalidomide emits visible light with a maximum at ~530 nm upon excitation at 420 nm. This emission was characterized and a library of pomalidomide PROTACs were synthesized and tested in vitro with osteosarcoma cells. In vitro fluorescence microscopy imaging of the pomalidomide library showed trends with linker structure. Relationships between fluorescence, target degradation and calculated partition coefficients were then explored.
dc.identifier.citationBrownsey, D. K. (2023). Exploration of pomalidomide for heterobifunctional protein degraders: from chemistry to application (Doctoral thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca.
dc.identifier.urihttp://hdl.handle.net/1880/116110
dc.identifier.urihttps://dx.doi.org/10.11575/PRISM/dspace/40956
dc.language.isoen
dc.publisher.facultyGraduate Studies
dc.publisher.institutionUniversity of Calgary
dc.rightsUniversity of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission.
dc.subjectPROTAC
dc.subjectPomalidomide
dc.subjectTarget Protein Degradation
dc.subject.classificationChemistry--Organic
dc.subject.classificationChemistry--Pharmaceutical
dc.titleExploration of Pomalidomide for Heterobifunctional Protein Degraders: From Chemistry to Application
dc.typedoctoral thesis
thesis.degree.disciplineChemistry
thesis.degree.grantorUniversity of Calgary
thesis.degree.nameDoctor of Philosophy (PhD)
ucalgary.thesis.accesssetbystudentI require a thesis withhold – I need to delay the release of my thesis due to a patent application, and other reasons outlined in the link above. I have/will need to submit a thesis withhold application.
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ucalgary_2023_brownsey_duncan.pdf
Size:
9.6 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.62 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Restricted Theses and Dissertations